Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years

Advances and Contributions

David M. Nathan; Margaret Bayless; Patricia Cleary; Saul Genuth; Rose Gubitosi-Klug; John M. Lachin; Gayle Lorenzi; Bernard Zinman


Diabetes. 2013;62(12):3976-3986. 

In This Article


The Diabetes Control and Complications Trial (DCCT)[1] and its observational follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) Study,[2] are celebrating the 30th anniversary since the start of the DCCT and 20th since the reporting of the DCCT primary results.[3] During the past three decades, our understanding of the relationship between metabolic control and complications and the treatment of type 1 diabetes (T1D) has been transformed by the results of DCCT/EDIC. Most importantly, the long-term prospects for patients have dramatically improved with the adoption of intensive therapy designed to achieve near-normal glycemia as the standard of care of T1D. In this Perspective, we present an overview of the major scientific advances provided by the DCCT/EDIC Research Group, the resulting changes in therapy that have improved long-term outcomes in patients with T1D worldwide, and the challenges that remain.